Academia Sinica yesterday approved the resignation of distinguished research fellow Chen Ching-shih (陳慶士) after news of research misconduct in eight of his published papers was made public by the Ohio State University, where he previously served as a cancer researcher.
Academia Sinica said in a statement that it is sorry to hear about the incident, but added that Chen’s misconduct occurred before he became head of Academia Sinica’s Institute of Biological Chemistry in August 2014.
The institution’s Research Ethics Committee would still look into work he performed while serving at the academy, the statement added.
Chen’s resignation from the Academia Sinica comes after academic journal Science and the university issued separate reports on Friday regarding the findings of research misconduct that led to his resignation as a cancer researcher from the university last year.
The reports said the investigation found Chen had “intentionally committed research misconduct” in 14 instances in eight journal articles, and was guilty of “deviating from the accepted practices of image handling and figure generation and intentionally falsifying data.”
Chen admitted to the charges and resigned in September last year, the university said.
The university said it has requested an “immediate retraction” of the papers, published between 2006 and 2014, that contain the fabricated data.
However, the implications of the misconduct go beyond unreliable academic papers, as Chen’s work had raised millions of US dollars in funding and led to multiple patents and the establishment of two compounds in clinical trials.
The university said it immediately shut down a clinical trial of one of Chen’s anti-cancer agents that Arno Therapeutics Inc had been conducting after obtaining exclusive rights to test the agents.
A spokesperson for the company said that issues with Chen’s papers had “zero impact” on its drug development efforts, Science said.
The university said it “hired an external consultant who validated that Chen’s research misconduct did not affect the Arno licensed compounds developed in his lab.”
“Patient safety was never compromised,” the university’s statement said.
The university said it has forwarded the investigation to federal authorities, meaning Chen could continue to be investigated for his actions.
Academia Sinica first became aware of the matter about a year ago, but it had limited access to Chen’s questionable articles because the university did not reveal its investigation on its Web site until Friday, Academia Sinica Central Academic Advisory Committee executive secretary Henry Sun (孫以瀚) said yesterday.
This is the worst punishment a Taiwanese academic has ever received from a foreign institution, dealing a heavy blow to the nation’s image in international academia, Sun said.
Sun quoted Chen as saying that his laboratory staff “beautified” data to make their research look better, and that he was responsible for lax supervision.
Yesterday morning, Chen’s profile was accessible on the Institute of Biological Chemistry’s Web site, but it was later taken down after Chen tendered his verbal resignation to Academia Sinica president James Liao (廖俊智).
Meanwhile, China Medical University, where Chen in February temporarily served as the director of its Institute of New Drug Development, yesterday said it is unclear about the matter and is collecting information about the case.
Before Chen returned to Taiwan to serve as director of the Institute of Biological Chemistry in August 2014 — a position he held until August last year — he had taught at the Ohio State University’s College of Pharmacy, the University of Rhode Island and the University of Kentucky.
Specializing in medicinal chemistry, cancer studies, biological chemistry and translational medicine, Chen has received research awards from the US Prostate Cancer Foundation and the Hearst Foundation, and is a fellow at the American Association for the Advancement of Science.
In April last year, he and National Cheng Kung University researchers found a relation between vitamin E and cancer prevention, and created an anti-tumor agent that is 20 times more efficient than previous ones, which was then considered a potential opportunity to develop a new anti-cancer drug.
WAITING GAME: The US has so far only offered a ‘best rate tariff,’ which officials assume is about 15 percent, the same as Japan, a person familiar with the matter said Taiwan and the US have completed “technical consultations” regarding tariffs and a finalized rate is expected to be released soon, Executive Yuan spokeswoman Michelle Lee (李慧芝) told a news conference yesterday, as a 90-day pause on US President Donald Trump’s “reciprocal” tariffs is set to expire today. The two countries have reached a “certain degree of consensus” on issues such as tariffs, nontariff trade barriers, trade facilitation, supply chain resilience and economic security, Lee said. They also discussed opportunities for cooperation, investment and procurement, she said. A joint statement is still being negotiated and would be released once the US government has made
Authorities have detained three former Taiwan Semiconductor Manufacturing Co (TMSC, 台積電) employees on suspicion of compromising classified technology used in making 2-nanometer chips, the Taiwan High Prosecutors’ Office said yesterday. Prosecutors are holding a former TSMC engineer surnamed Chen (陳) and two recently sacked TSMC engineers, including one person surnamed Wu (吳) in detention with restricted communication, following an investigation launched on July 25, a statement said. The announcement came a day after Nikkei Asia reported on the technology theft in an exclusive story, saying TSMC had fired two workers for contravening data rules on advanced chipmaking technology. Two-nanometer wafers are the most
NEW GEAR: On top of the new Tien Kung IV air defense missiles, the military is expected to place orders for a new combat vehicle next year for delivery in 2028 Mass production of Tien Kung IV (Sky Bow IV) missiles is expected to start next year, with plans to order 122 pods, the Ministry of National Defense’s (MND) latest list of regulated military material showed. The document said that the armed forces would obtain 46 pods of the air defense missiles next year and 76 pods the year after that. The Tien Kung IV is designed to intercept cruise missiles and ballistic missiles to an altitude of 70km, compared with the 60km maximum altitude achieved by the Missile Segment Enhancement variant of PAC-3 systems. A defense source said yesterday that the number of
Taiwanese exports to the US are to be subject to a 20 percent tariff starting on Thursday next week, according to an executive order signed by US President Donald Trump yesterday. The 20 percent levy was the same as the tariffs imposed on Vietnam, Sri Lanka and Bangladesh by Trump. It was higher than the tariffs imposed on Japan, South Korea and the EU (15 percent), as well as those on the Philippines (19 percent). A Taiwan official with knowledge of the matter said it is a "phased" tariff rate, and negotiations would continue. "Once negotiations conclude, Taiwan will obtain a better
RSS